Clinical trials: Respiratory Infections in Old Age
Covid19
Frailty in Elderly Patients With COVID-19
This is a multicentric retro-prospective observational study that wants to evaluate the relation between frailty and clinical outcomes in elderly patients with COVID-19.
- Trial name
- FRA-COVID (NCT04412265)
- Testing
- Relation between frailty and clinical outcomes in elderly patients with COVID-19.
- Where
- 6 sites in Italy
- Volunteers
- 1,344 people
- Sponsor
- University of Milano Bicocca
Influenza
Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population
The study is designed to demonstrate a meaningful difference in immunogenicity between the candidate adjuvanted vaccine compared to the licensed Fluarix vaccine in subjects aged 50 years and above.
- Trial name
- NCT00377585
- Testing
- Fluarix, adjuvanted influenza vaccine
- Where
- 30 sites in United States, Belgium and 2 more
- Volunteers
- 3,350 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)
The aim of the present dose ranging study is to evaluate the safety, tolerability and immunogenicity of two doses of twelve different formulations of a Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine, adjuvanted with…
- Trial name
- NCT00812019
- Testing
- Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59
- Where
- 2 sites in United States, Germany
- Volunteers
- 753 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea
This study is designed to assess the immunogenicity and safety of the 2010-2011 NH season formulation of intradermal (ID) influenza vaccine as part of a post registration commitment.
- Trial name
- NCT01215669
- Testing
- IDflu™: Split virion inactivated influenza vaccine, Vaxigrip®: Split virion inactivated influenza vaccine
- Where
- 2 sites in South Korea
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Covid19
Micronutrient Status Involved in Immunity in Elderly Patients With COVID-19
During the ongoing COVID-19 pandemic, age was clearly the major factor of mortality. Increasing age was strongly associated with this risk, with the upper 80 years age group having more than 12-fold increased risk compared with…
- Trial name
- MicroCovAging (NCT04877509)
- Testing
- Selenium, Zinc and Copper, Vitamin A, D, E plasma concentrations during patient hospitalization
- Where
- France
- Volunteers
- 229 people
- Sponsor
- Hospices Civils de Lyon
Influenza
Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older
The study will evaluate the safety, tolerability and immunogenicity of different doses and types of Influenza Vaccine in healthy elderly subjects.
- Trial name
- NCT00848848
- Testing
- Trivalent Influenza Vaccine, Trivalent Influenza Vaccine + high A, Trivalent Influenza Vaccine + ¼ dose adjuvant
- Where
- Belgium
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Seqirus
Age Problem, Surgery
Study on Incidence of Elective Surgery Postponed During COVID-19 Pandemic in Geriatric Population
The COVID-19 pandemic has disrupted routine hospital services globally. The hospital services include surgeries for benign diseases, cancer surgery and obstetric surgery.
- Conditions
- Age Problem, Surgery, Depression, Anxiety
- Trial name
- NCT04547218
- Where
- Malaysia
- Volunteers
- 150 people
- Sponsor
- University of Malaya
COVID-19
The Immunogenicity, Safety, and Effectiveness of the COVID-19 Inactivated Vaccine
To fast respond the coronavirus disease of 2019 (COVID-19) pandemic, the Indonesian government has launched "Vaksinasi Gotong Royong" (a mutual cooperation vaccination program) in which any company/legal entity/business entity…
- Trial name
- NCT05126550
- Testing
- SARS-CoV-2 vaccine (Vero cell) inactivated
- Where
- 4 sites in Indonesia
- Volunteers
- 435 people, healthy volunteers welcome
- Sponsor
- PT. Kimia Farma (Persero) Tbk